Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The prognostic role of CD133 expression in patients with osteosarcoma

Abstract

Osteosarcoma (OS), a malignant bone tumor, mainly occurs in adolescents. Cluster of differentiation 133 (CD133) is one of the most common tumor stem cell biomarkers. The prognostic significance of CD133 in OS has been reported, while the conclusions of these study were inconsistent. This study was conducted to investigate the association between CD133 expression and OS. We performed a search using several database including NCBI PubMed, Springer, CNKI, Web of Science and Wanfang for relevant papers about the prognostic value of CD133 on OS published before October 19, 2019. Pooled odds ratio (OR) and 95% CI were used to evaluate the outcomes. Seven reports including 498 OS patients were used for evaluating the association between CD133 positive expression and OS clinicopathological features. CD133 positive expression was not related to the age, gender, tumor size, tumor location and pathological type of OS. The expression of CD133 was significantly associated with high ennecking stage of OS (OR 9.67, 95% CI 5.56–16.80, P < 0.05) and OS local recurrence (OR 3.02, 95% CI 1.84–4.94, P < 0.05). In addition, the expressions of CD133 predict metastasis (OR 7.64, 95% CI 4.93–11.85, P < 0.05). Moreover, this study indicated that CD133 expression was correlated to lower 5-year overall survival in OS with the pooled OR of 5.85 (95% CI 3.30–10.37, P < 0.05). Our reported shown that positive expression of CD133 is significantly correlated with ennecking stage, local recurrence, metastasis and low 5-year overall survival rate of OS patients.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Abbreviations

CD133:

Cluster of differentiation 133

OS:

Osteosarcoma

CNKI:

China National Knowledge Internet database

CBM:

Chinese Biological Medical Database

NOS:

Newcastle–Ottawa Quality Assessment Scale

OR:

Odds ratio

95% CI:

95% confidence interval

References

  1. 1.

    Bertucci F, Araujo J, Giovannini M. Pancreatic metastasis from osteosarcoma and Ewing sarcoma: literature review. Scand J Gastroenterol. 2013;48:4–8.

  2. 2.

    Kong C, Hansen MF. Biomarkers in osteosarcoma. Expert Opin Med Diagn. 2009;3:13–23.

  3. 3.

    Ottaviani G, Jaffe N. The etiology of osteosarcoma. Cancer Treat Res. 2009;152:15–32.

  4. 4.

    Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.

  5. 5.

    Bao Y, Chen B, Wu Q, et al. Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7. Clin Exp Med. 2017;17:51–8.

  6. 6.

    Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28:247–63.

  7. 7.

    Wang X, Ning Y, Yang L, et al. Diagnostic value of circulating microRNAs for osteosarcoma in Asian populations: a meta-analysis. Clin Exp Med. 2017;17:175–83.

  8. 8.

    Li YJ, Dai YL, Zhang WB, Li SJ, Tu CQ. Clinicopathological and prognostic significance of chemokine receptor CXCR4 in patients with bone and soft tissue sarcoma: a meta-analysis. Clin Exp Med. 2017;17:59–69.

  9. 9.

    Han G, Wang Y, Bi W, Jia J, Wang W, Xu M. Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma. Clin Exp Med. 2016;16:577–84.

  10. 10.

    Gorlick R. Osteosarcoma: clinical practice and the expanding role of biology. J Musculoskelet Neuronal Interact. 2002;2:549–51.

  11. 11.

    Durnali A, Alkis N, Cangur S, et al. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients. Med Oncol. 2013;30:624.

  12. 12.

    Zhou J, Liu T, Wang W. Prognostic significance of matrix metalloproteinase 9 expression in osteosarcoma: a meta-analysis of 16 studies. Medicine (Baltimore). 2018;97:e13051.

  13. 13.

    Zhou J, Xiao X, Wang W, Luo Y. Association between PTEN and clinical-pathological features of osteosarcoma. Biosci Rep. 2019;39:BSR20190954.

  14. 14.

    Zhou J, Wang W, Yan Q, Luo Y. Expression of HER-2 in surgical specimen and biopsy as a biomarker of metastasis in patients with osteosarcoma: a meta-analysis. Transl Cancer Res. 2019;8:1129–36.

  15. 15.

    George W, Beverley JS, Dianne O, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. http://www.evidencebasedpublichealth.de/download/Newcastle_Ottowa_Scale_Pope_Bruce.pdf.

  16. 16.

    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

  17. 17.

    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.

  18. 18.

    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

  19. 19.

    Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

  20. 20.

    Xie Y, Huang J, Wu M, Zhou Y. Expression of CD133 protein in osteosarcoma and its relationship with the clinicopathological features and prognosis. J Cancer Res Ther. 2018;14:892–5.

  21. 21.

    Bao Z, Cheng Z, Chai D. The expressions of CD133, ALDH1, and vasculogenic mimicry in osteosarcoma and their clinical significance. Int J Clin Exp Pathol. 2018;11:3656–63.

  22. 22.

    Hong F, Yuan G, Zhang H, et al. Expression of microtubule instability protein and CD133 in osteosarcoma and its clinical significance. Chin J Exp Surg. 2017;3:516–8.

  23. 23.

    Qian T, Yu L, Zhang C, Zhou J. Increased immunohistochemical expression and angiogenesis of CD133 and ALDH1 in osteosarcoma. Chin J Histochem Cytochem. 2016;25:143–7.

  24. 24.

    Lin J, Lin J, Wu C, et al. Expression and clinical pathology of osteosarcoma CD133 CD117 Ki-67 correlation between factors and risk. Chin J Clin Oncol. 2014;41:305–10.

  25. 25.

    He A, Qi W, Huang Y, et al. CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: a clinical and experimental study. Exp Ther Med. 2012;4:435–41.

  26. 26.

    He A, Qi W, Tang L, et al. Expression of CD133 and CD44 in osteosarcoma and its clinical significance. Cancer Prev Res. 2012;39:1328–32.

  27. 27.

    Picci P, Mercuri M, Ferrari S, et al. Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol. 2010;21:1366–73.

  28. 28.

    Giebel B, Corbeil D, Beckmann J, et al. Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood. 2004;104:2332–8.

  29. 29.

    Bruno S, Bussolati B, Grange C, et al. CD133+ renal progenitor cells contribute to tumor angiogenesis. Am J Pathol. 2006;169:2223–35.

  30. 30.

    O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–10.

  31. 31.

    Tirino V, Desiderio V, D'Aquino R, et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS ONE. 2008;3:e3469.

  32. 32.

    Xiao D, Wang Y, Xu B. Introduction and inspiration of meta-analysis. Med Philos. 1998;19:179–182.

Download references

Funding

This work was supported by the Mittal Innovation Project of Central South University (Grant No. GCX20190879Y), the Fundamental Research Funds for the Central Universities of Central South University (Grant No. 2018zzts930), the Central South University Sports Medicine Scholarship, the National College Students’ Innovation and Entrepreneurship Training Program (Grant No. 201710422116).

Author information

NX, JZ, WW: Data curation. NX, YK, JZ: Formal analysis. NX, JZ: Funding acquisition. NX, JZ, WW: Investigation. NX, JZ, YK, WW: Methodology. JZ, YK, WW: Writing—original draft. JZ, WW: Writing—review & editing.

Correspondence to Yijun Kang or Wanchun Wang or Jian Zhou.

Ethics declarations

Conflict of interest

The authors wish to declare that there is no known conflict of interests associated with this publication.

Informed consent

All studies included in this study got informed consent from each study participant and that each study was approved by ethics committee or institutional review board.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

S1 Table. Qualitative assessment of included study. (DOCX 14 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xu, N., Kang, Y., Wang, W. et al. The prognostic role of CD133 expression in patients with osteosarcoma. Clin Exp Med (2020). https://doi.org/10.1007/s10238-020-00607-6

Download citation

Keywords

  • CD133
  • Bone tumor
  • Osteosarcoma
  • Clinicopathological features
  • Prognosis
  • Meta-analysis